Real-world study shows ofatumumab cuts MS relapses

NCT ID NCT06251986

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 18 times

Summary

This study looked at how well the drug ofatumumab (Kesimpta®) works in real-world Spanish clinics for people with relapsing multiple sclerosis. Researchers tracked 310 patients to see if the drug reduced the number of relapses (flare-ups of symptoms). The goal was to understand the drug's effectiveness and safety outside of a controlled trial setting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site

Palma, Balearic Islands, 07120, Spain
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Santander, Cantabria, 39008, Spain
Novartis Investigative Site

Albacete, Castille-La Mancha, 02006, Spain
Novartis Investigative Site

Salt, Girona, 17190, Spain
Novartis Investigative Site

Logroño, La Rioja, 26006, Spain
Novartis Investigative Site

Fuenlabrada, Madrid, 28942, Spain
Novartis Investigative Site

Majadahonda, Madrid, 28222, Spain
Novartis Investigative Site

Pamplona, Navarre, 31008, Spain
Novartis Investigative Site

Vigo, Pontevedra, 36212, Spain
Novartis Investigative Site

Santa Cruz, Santa Cruz de Tenerife, 38009, Spain
Novartis Investigative Site

Barakaldo, Vizcaya, 48903, Spain
Novartis Investigative Site

Alicante, 03010, Spain
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Burgos, 09006, Spain
Novartis Investigative Site

Cáceres, 10004, Spain
Novartis Investigative Site

Córdoba, 14004, Spain
Novartis Investigative Site

Granada, 18016, Spain
Novartis Investigative Site

León, 24080, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Madrid, 28040, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Madrid, 28046, Spain
Novartis Investigative Site

Málaga, 29010, Spain
Novartis Investigative Site

Seville, 41009, Spain
Novartis Investigative Site

Seville, 41013, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Novartis Investigative Site

Valencia, 46026, Spain
Novartis Investigative Site

Zaragoza, 50009, Spain

Conditions

Explore the condition pages connected to this study.

RELAPSING FORMS OF MULTIPLE SCLEROSIS